Other languages Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
60.6 ^USD	+1.80%		+4.68%	-27.42%

May. 17	Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors	CI
May. 15	Transcript : Cytokinetics, Incorporated - Shareholder/Analyst Call

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors	May. 17
Cytokinetics Q1 Net Loss Narrows, Revenue Declines	May. 08
Cytokinetics, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Cytokinetics, Incorporated Announces Topline Data from Phase 1 Clinical Study of Ck-4021586	May. 08
Cytokinetics, Incorporated Announces CEDAR-HCM Is Open to Enrollment	May. 08
Cytokinetics Insider Sold Shares Worth $1,012,265, According to a Recent SEC Filing	May. 07
Cytokinetics Appoints Sung Lee as CFO	Apr. 26
Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024	Apr. 26
Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing	Apr. 09
Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 05
Cytokinetics Reports Positive Follow-On Data for Prospective Heart Medication; Shares Rise	Apr. 05
Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session	Apr. 05
Cytokinetics Q4 Net Loss Narrows, Revenue Decreases; 2024 Outlook Issued	Feb. 27
Cytokinetics, Incorporated Provides Revenue Guidance for 2024	Feb. 27
Cytokinetics, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Cytokinetics, Incorporated Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27
Cytokinetics Insider Sold Shares Worth $960,625, According to a Recent SEC Filing	Feb. 13
Cytokinetics Insider Sold Shares Worth $2,585,497, According to a Recent SEC Filing	Feb. 06
Cytokinetics Insider Sold Shares Worth $994,625, According to a Recent SEC Filing	Feb. 02
Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw, Senior Vice President, Effective February 23, 2024	Feb. 02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Other languages

Filters